Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
about
Treatment of medulloblastoma with a modified measles virusOncolytic virus therapy for glioblastoma multiforme: concepts and candidatesMeasles to the Rescue: A Review of Oncolytic Measles VirusC-Terminal truncations of syncytin-1 (ERVWE1 envelope) that increase its fusogenicityIn situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines.Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersProstate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.Increasing the efficacy of oncolytic adenovirus vectorsGene therapy for malignant glioma.Mechanisms of Oncolysis by Paramyxovirus SendaiCombination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancerAttenuated oncolytic measles virus strains as cancer therapeuticsOncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.Replication-selective oncolytic viruses in the treatment of cancer.Intratumoral immunotherapy: using the tumour against itself.Affinity thresholds for membrane fusion triggering by viral glycoproteinsOncolytic measles virus strains as novel anticancer agents.Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.Advances in oncolytic virus therapy for glioma.Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents.Vesicular Stomatitis Virus G Glycoprotein and ATRA Enhanced Bystander Killing of Chemoresistant Leukemic Cells by Herpes Simplex Virus Thymidine Kinase/Ganciclovir.Oncolytic (replication-competent) adenoviruses as anticancer agents.Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.Oncolytic virotherapy for multiple myeloma: past, present, and future.Immunotherapy approaches in the treatment of malignant brain tumors.Immune and viral therapies for malignant primary brain tumors.Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.Enhanced cytotoxicity without internuclear spread of adenovirus upon cell fusion by measles virus glycoproteins.Antibody-targeted cell fusion.Effects of adenovirus-mediated SV5 fusogenic glycoprotein expression on tumor cells.Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.Hemagglutinin protein of measles virus induces apoptosis of HeLa cells via both extrinsic and intrinsic pathways.Viral mediated cell fusion: viral fusion--the making, or breaking, of a tumour?Review: Oncolytic virotherapy, updates and future directions.Myoblast fusion confusion: the resolution begins.Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancerFusogenic Viruses in Oncolytic Immunotherapy
P2860
Q24602003-56C4BE4B-C45F-48B0-B73A-A4A764B32F59Q27007519-B2EDDB5C-6AE9-433E-9598-6B0330F37EBBQ28072097-B58712A7-40D8-40D4-93C2-F81DDE63BAAFQ28256540-EF6B0048-1F2C-4E5A-9500-6DA619B8970AQ30832171-3E0A74F8-9C81-4EBA-9108-A2496B5923A8Q33652517-6ED5868C-0880-4AA9-AE12-78580BDD46DAQ33670645-D19EC7F4-D5FD-4922-97C7-11FD473D2BC1Q33985663-4794B45D-D8CC-4E02-8890-AD4F813272F5Q34292273-D0CFACB8-F589-43F8-BDE8-D0A5240AC034Q35261325-6BCFFB9F-6953-4CE6-A120-A13010693369Q35673628-78E15830-E626-4CE3-9EBC-39FF040FD431Q35721486-C65D2C0A-9A36-4B63-918C-2BDF4F4373E2Q35739482-FD359716-3D5D-4265-A707-07D12B2C3A04Q35818876-64303F55-85E8-425B-BA94-D51450B4004FQ35861936-3921AB72-0C0E-4AA0-BEB0-359A7E12EC35Q35912403-2F5655AC-AA37-450E-A1F4-1CB9CE578DD8Q35988030-9DCEFB47-5AA4-4812-A02E-DED852614463Q36315685-EA1D7EDA-4207-48E8-8A0E-4059ED627D27Q37261017-042911F5-0132-42BF-B8C1-C5B7AC746749Q37280354-40F46B43-65C5-48BB-A1C4-EFC37B4CACDBQ37287118-4303AF63-A55D-4E53-A1E3-11FCCDEF9813Q37628219-BB16DC84-6EB8-4887-BA6D-016B598A3A87Q37684212-AFC97DFF-70CE-4A4F-8DB9-262A01C74EB6Q37687415-CBE92896-2E95-40C6-8186-EC1159CFB6C2Q38754467-A6743C4D-FC73-42F9-8ACE-66D68E902268Q38803056-099703EC-C3ED-4639-A704-5AE228C759C3Q39016790-941B1C12-1160-4FF5-97E6-5598EDD1E6BEQ39168899-0BAF802D-935E-49A1-92B1-82F00C25B564Q40264235-652730AA-0A75-4035-AB3A-767ACDC90CB5Q40471271-DA3B4972-AF8F-4CE8-9213-0DF4A3EDD2BBQ40584431-175CBC7E-4404-4AB7-BAED-6F9F8920105DQ40641134-FBFF98AE-BBF3-4360-B5B1-B68498F41E03Q40653941-BB950AA5-50FD-44D8-B159-84C67002AD75Q42250695-B8DC2A77-EEB9-4D2D-91C7-FE0582EE1AD2Q45865364-2FBB3AA3-8ECA-4254-826E-7A8DFACE1E34Q47160989-1CAC6C4C-89BF-469C-BD4A-18BA31E0AF78Q48131580-D3C2BB18-5619-46E6-9EC6-F70957ED73C8Q56774608-F6BA01A5-A606-47F1-A79D-AB5C2C7F6842Q56971929-E14A05DA-D766-4536-AC20-F8DC9C4CC220
P2860
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
@en
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
@nl
type
label
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
@en
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
@nl
prefLabel
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
@en
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
@nl
P2093
P1433
P1476
Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
@en
P2093
Russell SJ
P304
P356
10.1089/104303401750148766
P577
2001-05-01T00:00:00Z